Testspace
Atezolizumab (anti-PD-L1-Antibody) | Avelumab (anti-PD-L1-Antibody) | Cemiplimab (anti-PD-1-Antibody) | Durvalumab (anti-PD-L1-Antibody) | Ipilimumab (anti-CTLA-4-Antibody) | Nivolumab (anti-PD-1-Antibody) | Pembrolizumab (anti-PD-1-Antibody) | Tislelizumab (anti-PD-L1-Antibody) | ||
| Lung | |||||||||
| NSCLC | 1L | ||||||||
| 2L | |||||||||
| Stage III | |||||||||
Last Update: 4. December 2024